Whether it’s a bull or bear market, TrendingWallStreet has you covered. Take a few minutes to register with us at http://www.trendingwallstreet.com/ to get exclusive access to our free stock reports.
Walgreen Co. (NYSE: WAG) shares closed up 3.69 percent on Friday with about 15 million shares traded. The stock was one of the most actively traded stocks on the NYSE. The company’s first quarter earnings soared 68 percent. Walgreen Co said Friday that it booked a total of $376 million in income during the quarter that ended Nov. 30 from its stakes in European health and beauty retailer Alliance Boots and U.S. pharmaceutical wholesaler AmerisourceBergen Corp.
Get more information on Walgreen Co. and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/WAG
Amarin Corporation plc (NASDAQ: AMRN) shares closed up 25.47 percent on Friday with nearly 27 million shares traded. The stock was one of the biggest gainers on the NASDAQ. Federal regulators appear to be considering a proposal by Amarin in regard to the structure of a drug study that could lead to wider uses for its fish-oil pill.
Get more information on Amarin Corporation plc and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/AMRN
Rite Aid Corporation (NYSE: RAD) shares closed down another 3.48 percent on Friday with about 77.7 million shares traded. The stock has been one of the biggest decliners on the NYSE for two straight trading days. The company released their earnings report noting a slight increase in revenue from the year-ago quarter, but cutting estimates for its fiscal year. The company now expects estimated earnings of between 17 cents and 23 cents per share for the fiscal year as opposed to the previous estimates of 18 cents to 27 cents per share.
Get more information on Rite Aid Corporation and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/RAD
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) shares closed up 48.95 percent on Friday with about 3.6 million shares traded. The stock was one of the biggest gainers in the NASDAQ and hit a new 52-week high of $13.69 during intra-day trading. The company successful results in a clinical trial testing the pharmacokinetic dose response of its oral insulin capsule (ORMD-0801) in type 1 diabetes patients.
Get more information on Oramed Pharmaceuticals Inc. and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/ORMP
Disclosure: TrendingWallStreet.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.
Leave a comment...